Spinoff Redvax sold to Pfizer

Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.

“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.

See also investor statement Redalpine blog.


Herpes and Influenza vaccines (update Feb 2016)

Redbiotec has generated a library of novel antigens for herpes simplex virus (HSV-2). The antigens are currently being tested with human blood samples for their potential as vaccine candidates.

Redbiotec is the commercial leader of an EU-funded program with the goal to develop a broadly protective Influenza vaccine.

Beyond its vaccine activities Redbiotec is exploring the broadening of its technology platform (materials science, microorganisms engineering)


Three new patents for Redbiotec's Herpes simplex vaccine program
Schlieren, 17 March 2016
Redbiotec has filed a new patent application covering its novel antigens against Herpes simplex viruses. The antigens developed by Redbiotec comprise potent trimers and dimers as well as combinations thereof. Redbiotec expects first results from its ongoing in vitro and in vivo studies by Q2 2016.
Redbiotec at J.P. Morgan 34th Healthcare Conference in SF
Schlieren, 20 November 2015
Redbiotec will attend JPM 34th Healthcare Conference in San Francisco starting January 11 2016. Redbiotec's delegation will include the two projects leaders of Redbiotec's HSV-2 vaccine and Universal Flu vaccine programs.
Further news